Adverum Biotechnologies, Inc. Logo

Adverum Biotechnologies, Inc.

Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.

ADVM | NDAQ

Overview

Corporate Details

ISIN(s):
US00773U2078
LEI:
Country:
United States of America
Address:
100 CARDINAL WAY, 94063 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Adverum Biotechnologies, Inc. is a clinical-stage company aiming to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The company develops potential functional cures to restore vision and prevent blindness. Its proprietary technology is a next-generation adeno-associated virus (AAV) vector platform for intravitreal (IVT) administration. Adverum's lead program, Ixo-vec (ixoberogene soroparvovec), is an investigational treatment for wet age-related macular degeneration (wet AMD). It is designed as a single, in-office injection that transforms retinal cells into 'biofactories' to continuously produce a therapeutic protein (aflibercept), thereby aiming to eliminate the need for frequent injections and offer a durable, long-term treatment benefit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Adverum Biotechnologies, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adverum Biotechnologies, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adverum Biotechnologies, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellectis S.A. Logo
Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.
United States of America CLLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.